If you work anywhere near the patient-access side of the pharmaceutical industry, you’ve probably heard the name Courier Health come up more than usual this year. Between a major funding round, a growing footprint at industry conferences, and new data on how badly the specialty pharma patient journey needs fixing, the company has quietly become one of the more talked-about names in health tech in 2026.
Here’s what’s actually happening, and why it matters for anyone tracking patient access trends in the U.S. this year.
What Courier Health Actually Does
Despite the name, Courier Health has nothing to do with delivery vans or package tracking. It’s a New York City-based technology company that builds a customer relationship management platform specifically for biopharmaceutical companies — one designed to manage what the industry calls the “patient journey,” the long and often bumpy road between a doctor writing a prescription and a patient actually getting on, and staying on, their medication.
That distinction matters because the gap between prescription and treatment is bigger than most people realize. Industry data cited by the company suggests that roughly 30% of patients who receive a specialty drug prescription never actually start the therapy, and around 70% discontinue within the first few months. For a patient managing a rare disease or a complex chronic condition, that’s not a minor inconvenience — it can mean the difference between disease control and a serious health setback. For drug manufacturers, it represents a persistent, expensive failure point that no amount of clinical innovation can fix on its own.
Courier Health’s platform is built to close that gap. It pulls together data that’s normally scattered across pharmacies, insurance companies, and separate patient support hubs into what the company calls a “Command Center” — a single dashboard that gives commercial teams a full view of where a patient is in their treatment journey. From there, the system helps identify patients who are at risk of falling off therapy, whether the cause is an insurance denial, a cost barrier, or simple confusion about next steps, and it consolidates communication channels like phone, text, email, and fax into one place so support teams aren’t juggling five different systems to reach the same person.
The Numbers Behind the Pitch
Founded by CEO Danny Sigurdson, Courier Health has reported some notable results from companies already using its platform: gains of more than 15% in patient start rates, a 67% reduction in the time it takes patients to begin therapy after being prescribed, and productivity increases for support teams that the company describes as sevenfold. Whether or not every biopharma client sees numbers exactly like that, the direction of the data lines up with a broader industry push toward measuring patient support the same rigorous way companies measure clinical outcomes.
That track record is likely a big part of why the company was able to close a $50 million Series B funding round this year, led by Oak HC/FT with continued participation from existing backers Norwest and Work-Bench. The new round brought Courier Health’s total funding to $70.5 million and is earmarked for continued product development, deeper investment in AI-driven capabilities, and expanding the team supporting the platform’s biopharma clients.
A Bigger Presence at ACCESS USA
Alongside the funding news, Courier Health has been building visibility at one of the industry’s key gathering spots: Informa’s ACCESS USA conference, held this year from March 17-19. This wasn’t the company’s first appearance at the event — it’s sponsored the conference in prior years as well — but its 2026 presence came with a higher profile, including a dedicated exhibit space and a panel discussion led by the company’s VP of Client Solutions, focused on what patient experience standards should look like going forward and how biopharma teams can better coordinate support and access efforts across the entire patient journey.
The panel’s framing reflects a theme showing up across the industry this year: the idea that patient support can no longer live in a silo. Hub services, specialty pharmacy relationships, payer coordination, and direct patient outreach have traditionally operated as separate functions with their own systems and their own teams. Courier Health’s pitch, echoed by others in the space, is that biopharma companies need those functions working from the same data and the same playbook if they want to actually move the needle on adherence.
Where This Fits in the Bigger Patient-Access Picture
Courier Health’s momentum this year is also a useful signal of where the broader patient-access conversation is heading in the U.S. Companies across the life sciences sector are grappling with the same underlying problem: therapies keep getting more specialized and more effective, but the infrastructure supporting patients through the process of actually accessing them has lagged badly behind. Fragmented data, manual processes, and a lack of visibility into what’s happening with an individual patient have been persistent pain points for years, and 2026 appears to be the year several parts of the industry are trying to close that gap at once — with AI-driven coordination tools, more integrated hub models, and a renewed emphasis on measuring patient-centricity as seriously as clinical trial data.
For biopharma commercial teams, the practical takeaway is that “patient experience” is no longer a soft, feel-good initiative sitting off to the side of the business. It’s increasingly treated as a measurable operational priority with real financial stakes attached — and companies like Courier Health are positioning themselves as the infrastructure layer that makes that possible.
Whether Courier Health remains the category leader as more players enter this space is still an open question. But for now, between the funding, the conference visibility, and the adoption numbers it’s reporting, the company is one of the clearer bellwethers for how seriously the industry is finally taking the last mile of patient access.
